Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.63 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.63 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495395 | 1.00 | AKR1B1 (0.69) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL2318176 | 0.87 | ALDH1A1 (0.67) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL30224951 | 0.87 | MAOB (0.53) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 | |
| Hydrochloric Acid SCHEMBL8858723 | 0.85 | ALDH1A1 (0.65) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL4248840 | 0.81 | AKR1B1 (0.71) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL5275063 | 0.81 | AKR1B1 (1.00) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL18397901 | 0.80 | AKR1B1 (0.69) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL10649648 | 0.80 | AKR1B1 (0.69) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL6331139 | 0.80 | ALDH1A1 (0.77) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 | |
| SCHEMBL5084426 | 0.80 | AKR1B1 (0.69) | AKR1B1KDM4EUSP2CSNK2A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260128372-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEMICAL LTD (KR) | 2026-05-07 | — | — | US | disclosed |
| EP-4576305-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2025-06-25 | — | — | EP | disclosed |
| CN-120153509-A | Nonaqueous electrolyte for lithium secondary battery and lithium secondary battery comprising same | 株式会社LG化学 | 2025-06-13 | — | — | CN | disclosed |
| CN-118666733-A | Application of tetrahydrocarbazole micromolecule compounds in preparation of antiviral drugs and preparation method thereof | 中国人民解放军空军军医大学 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024107030-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | 주식회사 엘지화학 | 2024-05-23 | — | — | WO | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| CN-109641864-B | Anti-infective agents | 邓迪大学 | 2023-04-04 | — | — | CN | disclosed |
| US-11485720-B2 | Anti-infective agents | UNIVERSITY OF DUNDEE (GB) | 2022-11-01 | — | — | US | disclosed |
| EP-3472141-B1 | ANTI-INFECTIVE AGENTS | UNIV DUNDEE (GB) | 2022-10-05 | — | — | EP | disclosed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-1606278-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1603911-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603912-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABOTT LABORATORIES | 2005-09-22 | — | — | US | disclosed |
| WO-2004083199-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083208-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083209-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083198-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| US-6552054-B1 | For prophylaxis and therapy of bone diseases and chondropathy | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-1211251-A1 | CHROMONE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485720-B2 | Anti-infective agents | C1R, RRS1, ARG1 | AKR1B1 2303/4885KDM4E 2159/4885USP2 3354/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | AKR1B1 1312/4885KDM4E 4640/4885USP2 1932/4885 |
| US-20260128372-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | CLCN2, CLIC1, RER1 | AKR1B1 604/4885KDM4E 3702/4885USP2 4637/4885 |
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | AKR1B1 1927/4885KDM4E 2305/4885USP2 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.